



Istituto Oncologico della Svizzera Italiana

Conferenze Formative IOSI 2024

Mercoledì dalle 12.00 alle 13.00 – Gli eventi si terranno in modalità ibrida, sia online che in presenza presso l'Auditorium all'Ospedale Regionale di Bellinzona e Valli – Bellinzona

- 24 gennaio **Optimizing the designs of early clinical trials in oncology**
Christina Yap, UK
Professor of Clinical Trials Biostatistics, The Institute of Cancer Research, United Kingdom
- 14 febbraio **Senolytic immune cells therapies for prostate cancer**
Andrea Alimonti, CH
Head of molecular oncology at the Institute of Oncology Research (IOR)
Full Professor of Oncology USI, ETH, CH
Full professor of Pharmacology UNiPD, IT
- 27 marzo **The changing landscape of relapsed and refractory diffuse large B-cell lymphoma**
Andrew Davies, UK
Professor of Haematological Oncology and Honorary Consultant, University of Southampton, UK
Chair UK National Lymphoma Research Group
Director Southampton Experimental Cancer Medicines Centre
- 17 aprile **Advances in DDR targeting: what can we expect in the next years**
Timothy A Yap, USA
Professor, Department of Investigational Cancer Therapeutics (Phase I Program)
Vice President, Head of Clinical Development, Therapeutics Discovery Division
Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
The University of Texas MD Anderson Cancer Center
- 15 maggio **Systematic reviews in a nutshell**
Giorgio Treglia, CH
Medical education and Research Area and Imaging Institute of Southern Switzerland, EOC, Bellinzona
Professor, Faculty of Biomedical sciences, USI, Lugano
Faculty of Biology and Medicine, UNIL, Lausanne
- 19 giugno **Management of antibody-drug conjugates toxicities**
Joseph Gligorov, FR
Professor of Medical Oncology Sorbonne Université
Medical Director of DMU ORPHé AP-HP Sorbonne Université
- 18 settembre **ctDNA and MRD in solid tumors: current state and future directions**
Umberto Malapelle, IT
Chair of Predictive Molecular Pathology Laboratory, Department of Public Health,
University Federico II of Naples, Italy
- 23 ottobre **New KRAS inhibitors beyond G12C**
Fabrice Barlesi, FR
General Director of Gustave Roussy
Professor of Medicine at the Paris Saclay University, France
- 20 novembre **Update on cellular therapies for solid tumours**
Andrew Furness, UK
Consultant Medical Oncologist, Solid Tumour Cellular Therapy Lead, The Royal Marsden NHS Foundation Trust
Team Leader and Clinical Lead, Centre for Translational Immunotherapy, The Institute of Cancer Research

Sponsor principale



Altri sponsor

